Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2007

View Archived Issues

Variation Biotechnologies raises Series A financing

Preclinical characterization of sergliflozin, a novel selective SGLT2 inhibitor

Poniard and Scripps Research Institute to discover FAK inhibitors

Icagen updates sodium channel programs

Scynexis earns preclinical milestone payment from Merck collaboration

AstraZeneca and Bristol-Myers Squibb collaborate on type 2 diabetes compounds

MultiCell's anticancer combination therapy prevents disease recurrence

Biomedical Research Models licenses Neuralstem compounds in diabetes

Valeant and Metabasis close pradefovir licensing deal with Schering-Plough

CytRx establishes new RNAi subsidiary, RXi Pharmaceuticals

Droxidopa reduces fall in orthostatic systolic blood pressure

Astellas terminates agreement on carperitide for acute heart failure

Progress in phase I study of anticancer compound ECO-4601

Valeant licenses Canadian rights to Xyrem in cataplexy

BioInvent and Genentech collaborate on cardiovascular candidate BI-204

Stimuvax begins phase III study

FDA outlines issues regarding planned phase I study of ReN-001 stem cell therapy

Metastatic pancreatic cancer patients show clinical responses to talabostat therapy

Sativex shows utility in peripheral neuropathic pain

Promising preclinical results with raloxifene-derived selective estrogen receptor modulator

Mycamine launched in 100 mg vial format

Somatuline Autogel NDA accepted for filing

Novel TAFIa inhibitor profiled at Berlex

Recent sanofi-aventis patents report novel therapeutic agents for arrhythmia

Novel treatment options for HIV infection reported in recent patent literature

Recent Gruenenthal patent discloses new analgesic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.